Literature DB >> 8074956

FDG-PET for the evaluation of tumor viability after anticancer therapy.

J Okada1, H Oonishi, K Yoshikawa, K Imaseki, K Uno, J Itami, N Arimizu.   

Abstract

To evaluate positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) as an diagnostic tool to determine tumor viability after anticancer therapy, fourteen patients were examined by FDG-PET after the end of the treatment. The lesions with residual viable tumor cells showed higher uptake of FDG than surrounding normal soft tissue. The lesions, in which tumor viability was lost or very low, showed higher uptake of FDG in four cases and similar uptake to normal soft tissue in three cases. The residual increased uptake of FDG was considered to be caused by remaining tumor cells and/or inflammatory reaction to anticancer treatment. FDG-PET after anticancer treatment should be interpreted by considering the reaction due to the treatment and the partial volume artifact of PET caused by the limited spatial resolution.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8074956     DOI： 10.1007/bf03165015

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN： 0914-7187            Impact factor:   2.668


  11 in total

1.  Quantitation in positron emission computed tomography: 1. Effect of object size.

Authors:  E J Hoffman; S C Huang; M E Phelps
Journal:  J Comput Assist Tomogr       Date:  1979-06       Impact factor: 1.826

2.  Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool.

Authors:  G Di Chiro
Journal:  Invest Radiol       Date:  1987-05       Impact factor: 6.016

3.  Estimation of local cerebral glucose utilization by positron emission tomography of [18F]2-fluoro-2-deoxy-D-glucose: a critical appraisal of optimization procedures.

Authors:  K Wienhard; G Pawlik; K Herholz; R Wagner; W D Heiss
Journal:  J Cereb Blood Flow Metab       Date:  1985-03       Impact factor: 6.200

4.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data.

Authors:  C S Patlak; R G Blasberg; J D Fenstermacher
Journal:  J Cereb Blood Flow Metab       Date:  1983-03       Impact factor: 6.200

5.  PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.

Authors:  U Haberkorn; L G Strauss; A Dimitrakopoulou; R Engenhart; F Oberdorfer; H Ostertag; J Romahn; G van Kaick
Journal:  J Nucl Med       Date:  1991-08       Impact factor: 10.057

6.  Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Authors:  R L Wahl; R L Cody; G D Hutchins; E E Mudgett
Journal:  Radiology       Date:  1991-06       Impact factor: 11.105

7.  Comparative regional analysis of 2-fluorodeoxyglucose and methylglucose uptake in brain of four stroke patients. With special reference to the regional estimation of the lumped constant.

Authors:  A Gjedde; K Wienhard; W D Heiss; G Kloster; N H Diemer; K Herholz; G Pawlik
Journal:  J Cereb Blood Flow Metab       Date:  1985-06       Impact factor: 6.200

8.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography.

Authors:  R Kubota; S Yamada; K Kubota; K Ishiwata; N Tamahashi; T Ido
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

9.  Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy.

Authors:  U Haberkorn; L G Strauss; A Dimitrakopoulou; E Seiffert; F Oberdorfer; S Ziegler; C Reisser; J Doll; F Helus; G van Kaick
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

10.  Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity.

Authors:  J Okada; K Yoshikawa; M Itami; K Imaseki; K Uno; J Itami; J Kuyama; A Mikata; N Arimizu
Journal:  J Nucl Med       Date:  1992-03       Impact factor: 10.057
View more
  3 in total

Review 1.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

Review 2.  Monitoring tumour response.

Authors:  J E Husband
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

3.  FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.

Authors:  N R Maisey; A Webb; G D Flux; A Padhani; D C Cunningham; R J Ott; A Norman
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.